Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
13
×
life sciences
national blog main
san francisco blog main
13
×
biotech
boston top stories
national top stories
san francisco top stories
clinical trials
new york blog main
indiana blog main
indiana top stories
new york top stories
san diego blog main
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
fda
national
boston
cancer drugs
deals
eli lilly
europe blog main
investing
roche
blueprint medicines
europe top stories
What
drug
13
×
medicines
cancer
fda
ipo
therapeutics
approval
new
approved
bio
blueprint
ceo
cholesterol
genetic
long
loss
lowering
market
marketing
medicine
muscle
patients
plan
pricing
research
ret
roundup
targets
therapy
treat
week
aces
acquisitions
address
advantages
affects
agency
ago
aimmune
allergy
Language
unset
13
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)